We are building a foundation
model for simulating clinical trials
Our solution leverages proprietary multimodal AI essential for tackling the complexities of multimodal biological systems.
Find out more
What we do
Ingenix is a proprietary multimodal and multiscale generative AI co-pilot for clinical development, created to enable accurate simulation of clinical trials on digital twins.
Our solution integrates biological and medical knowledge expressed via all applicable modalities, including through text, graphics, bioimaging, 3D structures, sequences, and time series, using the chain-of-thought prompting approach.
Ingenix’s AI foundation model is designed to understand multiple scales, ranging from molecular to cellular and populational levels. The complexity of human biology necessitates the model to perform a vast number of lower-level predictions rapidly before generating meaningful higher-level insights. At the molecular level alone, Ingenix’s model operates orders of magnitude faster than any other molecular docking model, paving the way for simulating drug interactions across the entire human proteome.
Who we are
Seasoned founders
Ingenix was co-founded by the founders of Applica, an AI-based start-up specializing in proprietary multimodal LLMs, acquired by Snowflake in 2022.
All-star AI team
Ingenix brings together the creators of Applica TILT, the researchers behind LongLLaMA, and AI scientists who have co-published with researchers at Google DeepMind.
Biotech pioneers
Our key biotech specialist has a Hirsch index of 30 and is ranked among the top influential 2% of scientists globally.
What You Get
Ingenix makes it possible to predict the outcome of clinical trials even for first-in-class drugs, which deploy new mechanisms of action.
Our model is based on actual comprehension of human biology, starting at the molecular level and continuing via the cellular, tissue, and organism levels to the level of the population.
Ingenix offers true granular prediction of clinical endpoint values and adverse events.
All genomic, transcriptomic, proteomic, and phenotypic data are assimilated for decisive functionality.
Ingenix provides a true co-pilot experience and lets users wield decision-making power.
Clinical investigators query our AI model using natural language and gain insights into the factors driving the predictions.
Who We’re For
The Ingenix mission is to build bridges between top scientists, pharma industry needs, and everyday benefits for millions of people worldwide. We are pushing the frontiers of AI with the best people on board and a budget that keeps us agile and innovative.
Pre-clinical development teams can deploy Ingenix to optimize drug candidate selection.
Strategy teams can use Ingenix to discern best-return research and development investments.
Clinical development teams gain insight into clinical endpoint values and outlier events with granular precision.
Why act now?
The pharma industry invests approximately $50 billion annually in clinical trials, yet nine out of ten pilot drugs fail to gain regulatory approval. What’s more, pharma is on the verge of a patent cliff with 41% of 2022 earnings resulting from products with patents expiring within six years.
Why act now?
To date, state-of-the-art AI models used for pharma have mainly been crafted by bioinformaticians, not AI-native scientists, which is why first wave AI-powered drug development companies have not managed to revolutionize the industry. Current AI models are not yet deeply multimodal and don’t understand human biology. However, advancements in large multimodal AI modeling are unlocking a real revolution in AI-based drug discovery. Ingenix is a next-wave company built around an AI-native and mathematics-proficient team trained in biology and ready to bring the GPT moment to the industry.
Importantly, the time to act is now because, at long last, the amount of publicly available high-quality training data is on the rise. Information available through UK Biobank, All of Us, or FinnGen is highly relevant and uniquely acquirable for the Ingenix model.
As for hard-to-get proprietary data, what is crucial to AI-powered drug development in the pre-clinical stages actually holds marginal value for the Ingenix foundation model, which is trained instead on multi-omics data, literature, and electronic health records. In fact, the data currently becoming available to Ingenix is precisely the data on which Ingenix learns best.
Why Ingenix
No other company is currently offering technology comparable to Ingenix AI. At the molecular level, Ingenix’s model operates orders of magnitude faster than any other molecular docking model, paving the way for simulating drug interactions across the entire human proteome. If you want to future-proof your clinical research, Ingenix is the answer.
Why Ingenix
Direct competitors are engineering AI to predict binary outcomes of clinical trials. And while determining success and failure may be good for hedge funds investing in pharma stock, it is by far insufficient for pharma itself. These other AI models are simple statistical machines that don’t understand human biology.
The Ingenix platform, in turn, uses chain-of-thought prompting to provide much more granular predictions, including clinical endpoint values and adverse events as well as insights into the factors driving the predictions. Through iterative querying of Ingenix AI, investigators can gain unprecedented insight into the factors driving the predictions.